Utomilumab
Utomilumab
Utomilumab (pronounced as yoo-toh-mi-LOO-mab) is a type of monoclonal antibody that is being studied in the treatment of certain types of cancer. It is a type of immune checkpoint inhibitor.
Etymology
The name "Utomilumab" is derived from the International Union of Pure and Applied Chemistry (IUPAC) nomenclature for monoclonal antibodies. In this nomenclature, "-lumab" is a suffix used to denote human antibodies.
Mechanism of Action
Utomilumab works by binding to a protein called PD-1 found on the surface of certain immune cells called T cells. By blocking PD-1, Utomilumab helps to boost the body's immune response against cancer cells.
Related Terms
- Monoclonal antibody: A type of protein made in the laboratory that can bind to substances in the body, including cancer cells.
- Immune checkpoint inhibitor: A type of drug that blocks certain proteins made by some types of immune system cells, such as T cells, and some cancer cells.
- PD-1: A protein on the surface of T cells that helps keep the body's immune responses in check.
Clinical Trials
Utomilumab is currently being studied in clinical trials for its effectiveness in treating various types of cancer, including melanoma, non-small cell lung cancer, and renal cell carcinoma.
External links
- Medical encyclopedia article on Utomilumab
- Wikipedia's article - Utomilumab
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski